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Abstract. In Primary Myelofibrosis (PMF), megakaryocyte dysplasia/hyperplasia determines the 
release of inflammatory cytokines that, in turn, stimulate stromal cells and induce bone marrow 
fibrosis. The pathogenic mechanism and the cells responsible for progression to bone marrow 
fibrosis in PMF are not completely understood. This review article aims to provide an overview 
of the crucial role of megakaryocytes in myelofibrosis by discussing the role and the altered 
secretion of megakaryocyte-derived soluble factors, enzymes and extracellular matrices that are 
known to induce bone marrow fibrosis. 
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Introduction. Bone marrow (BM) fibrosis is 
characterized by increased deposition of reticulin 
fibres and in some cases collagen fibres.1 There 
are a number of hematologic and non-hematologic 
disorders that are associated with increased BM 
fibrosis. In particular, reticulin fibres are 
composed by type III collagen and may be evident 
in many benign situations, including autoimmune 
and granulomatous diseases, and different tumors, 
such as lymphoid neoplasms, myelodysplastic 
syndromes, and acute myeloid leukemia. On the 
contrary, collagen fibres, are composed of type I 
collagen and appear to be characteristic of the 
advanced phases of myeloproliferative neoplasms 
(MPN), such as primary myelofibrosis (PMF) or 
secondary myelofibrosis (MF) arising from a pre-
existing diagnosis of polycythemia vera (PV) or 
essential thrombocythemia (ET).1 The content of 
BM fibres in routine sections of trephine biopsies 
of patients is usually demonstrated by 
histochemical staining using silver impregnation 
for reticulin fibres or by trichrome stains for 
collagen fibres. 
Recent evidence has shown that the amount of 
BM reticulin often exhibits no correlation to 
disease severity, while the presence of collagen 
fibres is often associated with more severe disease 
and a poorer prognosis.2 The exact pathogenesis of 
BM fibrosis is not fully understood. Aberrant 
tyrosine kinase signaling is a common hallmark in 
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MPNs and has been shown to represent a key 
driver of the disease. The three currently 
recognized driver mutations in PMF are JAK2 
(Janus kinase 2; located on chromosome 9p24), 
CALR (calreticulin; located on chromosome 
19p13.2), and MPL (myeloproliferative leukemia 
virus oncogene; located on chromosome 1p34). 
The JAK2 V617F substitution of a valine for a 
phenylalanine destabilizes the JH2 domain of 
JAK2 and causes loss of the auto-inhibitory 
activity of this domain.3 The most common MPL 
mutations, W515L (tryptophan-to-leucine 
substitution) and W515K (tryptophan-to-lysine 
substitution), cause both cytokine-independent 
growth and hyper-TPO sensitivity.4 JAK2V617F 
and MPL 515 mutations are present in about 50% 
and 5% of PMF cases respectively, resulting in 
permanent activation of the JAK/STAT signaling 
pathways and conferring in vitro altered response 
of mutated clones to thrombopoietin (TPO) and 
other cytokines.3,5 In 2013 type 1 mutations (52-bp 
deletion) and type 2 mutations (5-bp insertion) 
were discovered in the Calreticulin gene. These 
mutations determine a constitutive activation of 
the MPL receptor through abnormal interaction 
with mutated calreticulin.6,7 
Of the myeloproliferative disorders, PMF has 
the worst overall prognosis and morbidity.8 
Despite many significant advances in the treatment 
of this disease, many aspects of its origin and 
progression remain poorly understood. While 
recent understanding, on the pathogenic 
mechanisms in hematopoietic stem cells (HSCs), 
provides an explanation for myeloproliferation, 
several pieces of evidence clearly demonstrate that 
other processes are involved in this disease than 
the simple uncontrolled growth of mutant cells. In 
addition to BM fibrosis, the malignant stem cells 
exit from the BM as the disease progresses, and 
relocate in other hematopoietic organs, mostly the 
spleen and the liver.9 This leads to the enlargement 
of the spleen and liver that is characteristic of this 
disease, causing significant morbidity.10 In PMF 
the pathogenesis of myelofibrosis appears to be 
intimately linked with megakaryocyte (Mk) 
proliferation and differentiation.11 Mks have the 
primarily function to generate and release platelets 
in close proximity of BM vasculature,12 but they 
have also been shown to be involved in the control 
of BM homeostasis through the generation of 
signals that regulate HSC self-renewal and 
quiescence,13,14 or differentiation of others BM 
cell niche, such as plasma cells15 or osteoblasts.16 
In PMF clusters of immature and necrotic Mks, 
surrounded by fibrotic areas in the BM, suggests 
that improper or premature release of their neat 
cargo of intracellular proteins unleash the 
uncontrolled and disseminated fibrotic reaction 
driven by BM stromal cells.17 Noteworthy, Mks 
are very rich in cytokines, growth factors, cross-
linking enzymes and extracellular matrix proteins 
(ECM) that are known to directly cause tissue 
fibrosis by stimulating stromal cells to produce 
collagen or that physically participate to ECM 
remodeling and BM scarring. Thus, here we will 
review what is known about the potential 
contribution of Mks to the onset and progression 
of BM fibrosis. 
 
Megakaryocyte cargo in physiological 
thrombopoiesis. Mks are unique, polyploid 
hematopoietic cells that are found only in 
mammals, responsible for everyday production 
and release of millions of platelets into the 
bloodstream.18 
Megakaryopoiesis is mainly driven by TPO, 
although this cytokine may be dispensable for 
terminal megakaryocyte maturation in vitro.19 
During the early stages of their differentiation, 
Mks become polyploid through repeated DNA 
replication and endomitotic cycles without 
cytokinesis.20 At the end of maturation, the Mk 
cytoplasm becomes very specialized with the 
development of a complex system of membranes, 
called the demarcation membrane system (DMS), 
and three different types of granules including 
lysosomes, dense granules and -granules.20 
Proteins contained in the -granules (specialized 
secretory granules) can be synthesized or 
endocytosed.21 As in other cells, the cell-specific 
proteins are synthesized by ribosomes on the 
rough endoplasmic reticulum and then packaged 
via the Golgi apparatus into nascent granules.22 
Mk -granules are the most abundant secretory 
organelles and contain a large variety of adhesive 
proteins, such as -thromboglobulin, CXCL4 
(platelet factor 4, PF4), thrombospondin, 
fibronectin (FN), von Willebrand factor (vWF) 
and P-selectin. In addition, anti-angiogenic factors, 
endostatin and angiostatin, and pro-angiogenic 
factors such as VEGF and SDF-1, are involved in 
the regulation of lymphatic system development 
and vascular integrity promoted by -granule.23,24 
Mk -granules contain additional growth factors 
for vascular repair, such as Platelet Derived 
Growth Factor (PDGF), Transforming Growth 
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Factor-1 (TGFβ1), Epidermal Growth Factor 
(EGF) and Insulin Growth Factor (IGF).25 
Furthermore, members of the metalloproteinases 
(MMP) and tissue inhibitors of metalloproteinases 
(TIMP) family, which are important factors in 
angiogenesis and tissue remodeling, are also 
stored in Mk cytoplasm.26 In addition, these 
granules have been shown to contain several 
plasma proteins, such as fibrinogen,27 Factor V, 
albumin and immunoglobulin,28 which are not 
synthesized by the cell and are, therefore, 
endocytosed. Lastly, the pro-coagulant factors II, 
V, XI and XIII, high molecular weight kininogens, 
the anti-fibrinolytic factors plasminogen activator 
inhibitor-1, 2-antiplasmin and carboxypeptidase 
B2, anti-coagulant factors, for example, 
antithrombin, protein S, C1-inhibitor, TFPI and 
protease nexin 2 and pro-fibrinolytic proteins such 
as plasminogen and plasmin have been all 
localized in -granules.25 
Differently from -granules, secretory 
lysosomes contain distinct acid hydrolases, such as 
beta- hexosaminidase, heparanase, elastase, and 
cathepsin D and E.29 Finally, Mk dense granules 
store small bioactive molecules, while -granules 
are predominantly protein-packed. The cargo 
comprises nucleotides (e.g., ADP, ATP), 
polyphosphates, Ca2+ and Mg2+ cations, but also 
neurotransmitters and hormones, such as serotonin 
and histamine.30 
 
How do megakaryocytes target and deliver 
their protein cargo within bone marrow milieu? 
The constitutive in vitro secretion of both - and 
dense granules-derived bioactive molecules by 
developing Mks has been previously 
demonstrated.31,32 These functional experiments 
revealed that secretion of intracellular Mk 
products governs autocrine mechanisms that 
sustain cell development and platelet release.33-36 
On the contrary, the physiological in vivo 
relevance of these autocrine loops has been less 
explored. However, recent data shed new light on 
the in vivo involvement of Mks in maintaining BM 
homeostasis though the controlled release of 
targeted stimuli.37 To this regard, conditional 
ablation of Mks in mice resulted in increased BM 
HSC frequency and cycling, suggesting that Mks 
normally restrain HSC proliferation through the 
production of CXCL4 and TGF-.13,14 Conversely, 
Mk production of fibroblast growth factor-1 (FGF-
1) is thought to play a key role in supporting HSC 
and osteoblast expansion recovery following 
myeloablative therapy.16 Therefore, these studies 
raise the fundamental question: how is Mk 
compound exocytosis regulated during 
physiologically or pathologically BM functions? 
Differently from Mks, platelet activation is at the 
heart of the control of vascular integrity.38 During 
circulation, platelets are reactive to various stimuli 
and release the materials stored in their specific 
granules.39 The extrusion of storage granules' 
content to the platelet's environment occurs 
according to regulated secretion events: 
movements of granules, apposition and fusion of 
granules and plasma membranes.40 This 'release 
reaction' is a key step of primary hemostasis, but it 
participates also in inflammation, atherosclerosis, 
antimicrobial host defense, wound healing, 
angiogenesis, and malignancy.41 Our current 
understanding of Mk/platelet secretion at the 
molecular level is still insufficient to explain how 
the careful balance between all the bioactive 
molecules released from granules, under certain 
activation conditions, is achieved. One of the 
hypotheses is that Mk/platelet granules are not 
uniform and may be differentially packaged and 
thus released in a segregated manner following 
specific stimuli.42 
To this regard, Ma et al. observed that platelet 
stimulation with specific protease-activated 
receptor- 1 (PAR-1) or PAR-4 agonist resulted in 
the preferential release of VEGF or endostatin 
(anti- and pro-angiogenic factors, 
respectively).24,43 More recently, a super-resolution 
immunofluorescence co-localization analysis of 15 
platelet α-granule cargoes failed to confirm any 
functional co- clustering of these proteins.44 
Moreover, Zingariello et al. demonstrated by 
immunoelectron microscopy that P-selectin and 
von Willebrand factor (vWF) are co-localized 
within the same intracellular α-granules in 
immature Mks. The two proteins, however, are not 
co-localized in α- granules of mature Mks after 
wild type mice treatment with TPO.45 These 
results suggested that P- selectin and vWF are 
associated in the Mk cytoplasm at early stages of 
maturation but that they are routed into separate 
anti-angiogenic or pro-angiogenic α-granule 
subtypes as these cells mature. Thus, the 
differential association of vWF and P-selectin with 
anti-angiogenic or pro-angiogenic factors suggest 
that a mechanism regulating the sequential release 
of different α-granule subtypes may be involved in 
Mk/platelet function during tissue repair.45 
Interestingly, Mks derived from the GATA-1low 
   www.mjhid.org Mediterr J Hematol Infect Dis 2018; 10; e2018068                                                        Pag. 4 / 18 
mice, which harbors a hypomorphic mutation that 
blocks Mk maturation and displays BM fibrosis, 
showed reduced levels of expression of vWF and 
displaced P-selectin on the demarcation membrane 
system. 
Further, the loss of alpha granules within BM 
Mks in a mouse model of Gray Platelet Syndrome 
(GPS) induced a myelofibrotic phenotype.46 In 
PMF patients, ultrastructural abnormalities and 
variety in Mk-granules were reported by Thiele et 
al. more than 25 years ago.47 Platelets derived 
from MPN patients showed several qualitative 
abnormalities, including decreased alpha granules 
and mitochondria and also alterations of the dense 
and tubular canalicular system.48 Reduced levels 
of ADT, ATP and serotonin content in dense 
granules and lower content of beta-
thromboglobulin (BTG) and platelet factor 4 (PF4) 
in alpha granules were also described.49,50 Thus, 
aberrant assembly and secretion of Mk granules 
represent a potential mechanism of BM fibrosis 
progression (Figure 1). 
A second intriguingly hypothesis is that 
intracellular Mk/platelet products may be 
delivered in the surrounding space by extracellular 
vesicles (EVs). EVs are membrane-enclosed 
structures of varying size (50-10,000 nm) released 
from cells to mediate both local and distant 
intercellular communication.51 EVs of various 
shapes and sizes have been demonstrated in 
several body fluids, with substantial variation in 
their structure, content and function.52 There are 
three main types: exosomes (50-100 nm), 
microparticles (200 nm-1 m) and apoptotic 
bodies. Protein, lipid and RNA components 
contribute to cell-cell crosstalk at a short distance, 
in a paracrine or endocrine manner via the 
bloodstream. In addition, they may transfer surface 
receptors from one cell to another and deliver 
proteins, mRNA, bioactive lipids, and even whole 
organelles (e.g., mitochondria) into target cells.53 It 
has been reported that two mechanisms used by 
target cells to integrate EVs are cell endocytosis 
and membrane fusion.53 Recent studies of EVs in 
the BM have shown that these vesicles serve to 
regulate hematopoiesis, participate in immune cell 
activation, and hemostasis.54,55 Several lines of 
evidence suggest that EVs are involved in 
regulating BM function during homeostasis and in 
response to injury, but also that hematological 
malignancies such as leukemia, multiple myeloma 
or viral infections can exploit EVs trafficking to 
reinforce tumor growth, chemotherapeutic 
resistance, invasion and metastasis.56,57 Platelet-
derived vesicles were first identified by electron 
microscopy over 50 years ago, but the definition 
of their features and activities have only become a 
major focus of interest in recent years.58 Platelet-
derived microparticles (PMPs) are released from 
the platelet surface and are distinguished from 
platelet exosomes, which are derived from 
endocytosis and released from multivesicular 
endosomes.59 PMPs may directly stimulate other 
cells (e.g., hematopoietic cells, lymphocytes and 
endothelium),60 transfer platelet expressed 
receptors (e.g., CD41 or CXCR4) to the surface of 
other cells,61 and, in some situations, transfer 
mRNA, proteins, and even infectious particles to 
the target cells. Interestingly, in healthy donors, 
the majority of circulating CD41+ PMPs do not 
express surface activation marker CD62P, 
suggesting that they do not originate from 
activated platelets.62 In a very elegant study, 
Flaumenhaft et al. report that a significant number 
of circulating CD41+ MPs in healthy individuals 
are derived directly from Mks.63 Authors first 
demonstrated via electron microscopy of 
spontaneous formation of Mk-derived MPs 
(MkMPs) from cultured murine Mk and that these 
MkMPs were different from PMPs. However, a 
functional role for MkMPs was not revealed until 
a recent study, which documented a novel 
biological role of MkMPs that are able to induce 
HSC differentiation towards the Mk lineage 
without exogenous TPO stimulation.64 In this 
paper, Jiang et al. demonstrated that MkMPs, 
which are distinct from Mk exosomes, target HSC 
with high specificity since they have no effect on 
other BM-resident cells, such as mesenchymal 
stem cells, endothelial cells or granulocytes. They 
showed that both endocytosis and membrane 
fusion were responsible for the delivery of MkMP 
cargo to HSCs, and that MkMPs attached to and 
entered HSCs preferentially through their uropods, 
with CD54, CD11b, CD18 and CD43 being 
involved in target-cell recognition.64 Aside from 
the role of EVs in the Mk-HSC crosstalk in the 
BM under physiological conditions, we can 
speculate that EV trafficking may also play a 
distinct role in deregulated hematopoiesis during 
fibrotic progression (Figure 1). Interestingly, 
increased MP generation under high shear stress 
has been reported in platelets in the presence of 
TPO,65 a main trigger of BM fibrosis in human 
and mice. 
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Figure 1. Schematic representation of potential mechanisms for aberrant release of Mk content in bone marrow fibrosis.  
 
Megakaryocyte-derived pro-fibrotic cytokines 
in bone marrow fibrosis. In MPNs different 
mutations lead to myelofibrosis. The most 
frequent driver mutation in MPNs, JAK2 V617F, 
is found in 50-60% of PMF as well as 50-60% of 
ET, but in almost all cases of PV.66 It is now clear 
that the clinical phenotype of myelofibrosis is a 
consequence both of primary clonal 
myeloproliferation and secondary inflammation, 
characterized by profound changes to BM stromal 
compartment and an atypical cytokine storm.67 
Several evidences argue for an impaired 
microenvironment in association with 
inflammation rather than one single genetic 
trigger: 1) MPNs (PV, ET, and PMF) are all 
characterized by a significant change in the 
cytokine production mirrored by increased plasma 
levels of several inflammatory cytokines (e.g., 
IL1, IL2, IL6, IL8, IL12, TNF𝛼, and IFN𝛾), 
growth factors (e.g., GM-CSF, G-CSF, HGF, 
PDGF, and EGF), and angiogenic factors (e.g., 
VEGF);68 2) clinical evidences that chronic 
inflammation is responsible of the constitutional 
symptoms which negatively affect the quality of 
life of MPN patients;69 3) clinical use of JAK 
inhibitors has confirmed that functional symptoms 
and splenomegaly in patients were concomitant  
with a significant increase in the plasma levels of 
many cytokines.70 
In PMF, Mks and monocytes are supposed to 
be the main source of reactive cytokines that force 
fibroblast proliferation, fibrotic evolution, 
neoangiogenesis, and osteosclerosis.11 Several 
lines of evidence obtained both from studies of 
patients or murine models are in favor of a crucial 
role of Mk in myelofibrosis induction: 1) all driver 
mutations in MPNs result in overproduction of 
abnormal Mks by hyperactive Jak2/Stat 
signaling;71 2) mice bearing a human JAK2V617F 
gene restricted exclusively to the Mk lineage 
develop many of the features of MPNs;72 3) 
patients and rats treated with TPO mimetics show 
BM fibrosis (usually reversible);73 4) high and 
persistent TPO production by transduced 
hematopoietic cells in mice results in a fatal 
myeloproliferative disorder that has a number of 
features in common with human PMF;74 5) 
impaired expression of the transcription factor 
GATA-1, involved in erythroid and 
megakaryocytic differentiation, results in the 
development of myelofibrosis;75 6) patients with  
GPS, a rare macro-thrombocytopenia with 
agranular Mk/platelets, manifest myelofibrosis and 
splenomegaly.76 On the contrary, contribution of 
monocytes is less clear. Monocytes from patients 
with PMF were reported to be spontaneously 
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activated and to secrete abnormally TGF-β1,77 
however, TPO overexpression inducing BM 
fibrosis in NOD/SCID mice, which harbor 
impaired mononuclear phagocyte functions, led to 
controversial data.78,79 Thus, based on the potential 
role of inflammation during fibrotic progression, 
we below describe the involvement and features of 
individual main Mk- derived 
cytokines/chemokines in the context of 
myelofibrosis (Table 1). 
 
Platelet-Derived Growth Factor (PDGF). 
PDGF is one of the first growth factors that has 
been implicated in the role of Mk in development 
of BM fibrosis.80 PDGF is produced by Mks in the 
BM and is physiologically carried to the 
circulation in the α-granules of the platelets to act 
at the site of tissue injury as a mediator of tissue 
repair.81 PDGF receptors (PDGFRs) are members 
of the membrane tyrosin-kinase family, composed 
of the two subunits PDGFRα and PDGFRβ, which 
form homo- or heterodimers. In the context of 
tissue repair, the PDGF/PDGFR axis not only 
enhances the replication, survival, and migration 
of myofibroblasts but also modulates the 
production and release of several pro- and anti-
inflammatory mediators in fibrotic diseases.82 
Interestingly, PDGF has been reported to increase 
the expression of the collagen cross-linking 
enzyme, Lysil Oxidase (LOX), which in turn, 
oxidizes the PDGF receptor on smooth muscle 
cells, fibroblasts, and Mks, enhancing the 
proliferation signaling from this cytokine.83,84 
Ultimately, this loop has the potential to further 
boost the fibrotic phenotype.85 
Increased levels of PDGF in plasma and urine 
from patients with MPNs have been reported.86,87 
Further, Mks and erythroid precursors contained 
increased levels of immunohistochemically 
detectable PDGF in BM biopsies of PMF 
patients.88 The expression of members of the 
PDGF system in BM cells derived from PMF 
patients has been also investigated by real-time 
RT-PCR.  
Increased expression of PDGFs could be 
demonstrated to be a feature of advanced fibrosis 
in PMF that is not demonstrable in the pre-fibrotic 
phase of the disease.88 
Differently from their ligands, up-regulation of 
both PDGFRs during fibrotic progression is more 
controversial. In normal BM PDGFRα appeared in 
endothelial and endosteal cells in addition to 
strong labeling in Mks and platelets. In contrast, 
PDGFRβ subunit marked perisinusoidal stromal 
cells and adventitial fibrocytes of the larger 
vessels. However, in PMF patients, Bedekovics et 
al. found that PDGFRβ expression closely 
correlates with the grade of MF, while this was not 
evident for PDGFRα.90 On the contrary, Bock et 
al. reported a strong up-regulation of the PDGFR 
in patients with advanced myelofibrosis.89 
Recently, the involvement of the 
PDGF/PDGFR axis in BM fibrosis has been 
definitively proven. Conditional deletion of the 
PDGFR-α gene and inhibition of PDGFRα by 
imatinib in leptin receptor+ stromal cells was 
shown to suppress their expansion and to 
ameliorate BM fibrosis in mice.91 
 
Transforming Growth Factor- (TGF-) Among 
the abnormally expressed cytokines in PMF, TGF-
β1 has received attention due to its critical role in 
inducing fibrosis not only in BM, but also in other 
organs.92 TGF-β occurs in 3 isoforms: TGFβ1, 
TGFβ2 and TGFβ3. TGFβ1 is the most abundant 
of all these isoforms and platelets, Mks and 
monocytes cells are sources of TGF-β 
production.93 TGFβ1 is secreted as latent protein 
and is stored in the extracellular matrix. Reactive 
oxygen species, proteases, integrins and 
thrombospondin-1 (TSP-1), convert the inactive 
latent complexes to the active forms. 
Once activated, TGFβ-1 induces BM fibrosis on 
one hand, by increasing the synthesis of types I, III 
and IV collagen, FN, proteoglycans and tenascin;94 
while on the other hand, by decreasing matrix 
degradation through down-regulation of 
metalloproteinases (MMPs), particularly MMP3, 
and up- regulation of tissue inhibitors of 
metalloproteinase (TIMP), particularly TIMP-1.95 
However, effects of TGF-1 are not restricted to 
the stromal compartment and TGF-β1-mediated 
changes to the BM niche remain to be fully 
elucidated. It is well known that TGF-β has direct 
effects on hematopoietic cells by negatively 
regulating granulocyte, erythroid, Mk and 
macrophage progenitor proliferation.96 Further, 
Erba et al. showed that release and activation of 
TGF-β1 by Mks and platelets, forced endothelial 
cells from the BM microvasculature of PMF 
patients, and mouse model of PMF, to acquire a 
mesenchymal phenotype through Endothelial 
Mesenchymal Transition (EndMT), during the 
development of fibrosis.97  
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Table 1. List of Mk-derived cytokines implicated in bone marrow fibrosis progression. 
Soluble factor Mechanism of action Evidences from mice models Patient specimens Ref. 
Transforming Growth 
Factor- (TGF-) 
- Increases the synthesis of types I, III and IV collagen, FN, 
proteoglycans and tenascin in stromal cells. 
- Down-regulation of metalloproteinases (MMPs) and up-
regulation of tissue inhibitors of metalloproteinase (TIMP). 
- Favor Endothelial Mesenchymal Transition (EndMT). 
- Significantly increased in the extracellular fluid of 
the BM, plasma and platelet extracts in the TPOhigh 
and the GATA-1low mice. 
- Homozygous TGF-1 null mice are protected from 
reticulin deposition after TPO overexpression. 
- Quantitative alterations of TGF-β and its receptors 
in Mk, platelets, and CD34+ progenitor cells from 
MPN patients. 
- Aberrant TGF- signaling in BM and spleen of 
PMF patients. 
31, 89-96 
Platelet Derived 
Growth Factor (PDGF) 
- Enhances the replication, survival, and migration of 
myofibroblasts but also modulates the production and release 
of several pro- and anti-inflammatory mediators. 
- Conditional deletion of the PDGFR-α gene and 
inhibition of PDGFR- by imatinib in leptin 
receptor+ stromal cells suppress their expansion and 
ameliorate BM fibrosis in mice 
- Increased levels of PDGF in plasma and urine from 
patients with MPNs 
- Up regulation of PDGFRs and PDGF in BM 
biopsies of PMF patients. 
78-79, 81-
85 
Fibroblast Growth 
Factor (FGF) 
Basic FGF is a potent angiogenic factor 
(Folkman & Klagsbrun, 1987); moreover, it is a mitogen 
for human bone marrow stromal cells 
Basic FGF is a potent angiogenic factor 
(Folkman & Klagsbrun, 1987); moreover, it is a mitogen 
for human bone marrow stromal cells 
- Sustains angiogenesis and is a potent mitogen factor for 
stromal cells. 
N/A 
- Increased expression in circulating Mks and 
platelets of PMF patients. 
125 
Vascular Endothelial 
Growth Factor (VEGF) 
- Angiogenic factor N/A 
- Significantly higher level of VEGF in plasma 
samples of MPN patients. 
126 
Thrombospondin 
- Anti-angiogenic factor 
- TGF-  activator 
- Tsp-1-null/TPOhigh mice develop a myelo-
proliferative syndrome with higher grade compared 
to wild type mice. 
- Significantly overexpressed in BM biopsies of PMF 
patients when compared to controls. 
128-129 
CXCL4 (PF4) - Induce activation and migration of myofibroblasts N/A 
- No correlation between BM fibrosis and plasma 
levels or the platelet content of CXCL4 in MPN 
patients. 
107-108 
Macrophage 
Inflammatory Protein 
1 and 1  
- Pro-inflammatory chemokines 
- Increased levels in Mks of NBEAL2-/-, a GPS 
mouse model which display BM fibrosis. 
- Increased in plasma samples of PMF patients. 116-117 
Interleukin-8 
- Stimulates neutrophil chemotaxis 
- Sustains neo-angiogenesis 
- Negative regulator of Mk proliferation 
N/A - IL-8 level is strongly increased in the serum and 
plasma of patients with PMF 
63, 120 
Lipocalin-2 (LCN2) 
- LCN2 generates increased reactive oxygen species, leading 
to increased DNA strand breaks and apoptosis of normal, but 
not PMF, CD34(+) cells. 
- Increases generation of osteoblasts and fibroblasts, but not 
adipocytes, from mesenchymal stem cells. 
N/A - Increased in plasma samples of PMF patients. 124 
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Secreted phospho-
protein 1 (Spp1) 
- SPP1 promotes fibroblasts and mesenchymal stromal cells 
proliferation and collagen production 
N/A 
- SPP1 plasma levels are significantly higher in PMF 
compared with ET and PV patients. 
- Higher SPP1 plasma levels in PMF patients 
correlate with a more severe fibrosis degree and a 
shorter overall survival 
127 
Bone morphogenic 
proteins (BMPs) 
- BMP-1 is an activator of latent TGF- and processor of 
collagen precursors. 
N/A 
- Expression of BMP1, BMP6, BMP7, and BMP-
receptor 2 are significantly increased in advanced 
stages of myelofibrosis compared with controls 
122-123 
Oncostatin M 
- Stimulates growth of fibroblasts and microvascular 
endothelial cells and induces the production of angiogenic 
and profibrogenic cytokines (HGF, VEGF, and SDF-1) in BM 
fibroblasts. 
N/A 
- OSM mRNA levels are increased in the BM of 
patients with MPNs compared to control patients 
114-115 
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Not surprisingly, several groups reported on 
quantitative alterations of TGF-β and its receptors 
in Mk, platelets, and CD34+ progenitor cells from 
MPN patients and concluded that TGF-β was 
involved in myelofibrosis and 
myeloproliferation.31,98-100 In addition to 
quantitative alterations, Ciaffoni et al., recently 
demonstrated abnormalities in TGF-β1 signaling 
genes in the marrow and spleen of PMF 
patients.101 These alterations included genes of 
TGF-β1 signaling, cell cycling, Hedgehog and p53 
signaling and suggested a non-canonical TGF-β1 
signaling in marrow identifying, for the first time, 
autoimmunity as a possible cause of BM fibrosis 
in PMF.101 Among the genes that predict the 
activation of the non-canonical TGF-β signaling, 
expression level of the Jun gene was increased in 
BM of PMF patients. Interestingly, over-
expression of Jun was sufficient to induce 
myelofibrosis, severe fibrosis in multiple organs 
and steatohepatosis in mice.102 
Moreover, the involvement of TGF- in in vivo 
mouse model has been deeply investigated. TGF-β 
was significantly increased in the extracellular 
fluid of the BM, plasma and platelet extracts in 
two widely MF studied mouse models, which 
include the TPOhigh and the GATA-1low mice.103,104 
To test directly the impact of TGF-1 in the 
pathogenesis of MF, BM stem cells from 
homozygous TGF-1 null (TGF-1(-/-)) and wild-
type littermates were infected with a retrovirus 
encoding the murine TPO protein and engrafted 
into lethally irradiated wild type hosts for long-
term reconstitution. Differently from wild type 
mice, none of the mice repopulated with TGF-1(-
/-) cells showed deposition of reticulin fibres at 
any time during the follow-up.105 Consistently 
with patient data, alterations of TGF-β1, 
Hedgehog, and p53 signaling pathways were 
identified in the BM of GATA- 1low mice 
model.106 Inhibition of TGF-β1 signaling in these 
mice by an inhibitor of the tyrosine kinase activity 
of TGF-β1 receptor type I, led to restoration of 
normal Mk development, reduced fibrosis, 
neoangiogenesis, and osteogenesis in the BM.106 
Based on these consistent observations, TGF-β 
inhibition has become a potential therapeutic 
strategy to decrease BM fibrosis in MPNs and is 
also being investigated in several clinical and 
experimental scenarios.107 
 
Cxcl-4 (Pf-4). Cxcl-4, (C-X-C motif) ligand 4 
(CXCL4) (also known as platelet factor 4 [PF4]), 
is one of the most abundant protein in the α-
granules of Mk/platelets (estimated micromolar 
concentration), together with CXCL7.108 This 70 
a.a., cationic, lysine-rich, 7.8-kDa chemokine, is 
mainly synthesized by Mks, and comprises 2%-
3% of the releasate from agonist-activated 
platelets. Once secreted, CXCL4 avidly binds to 
glycosaminoglycans, but only a splice-variant of 
the human chemokine receptor CXCR3 
(CXCR3B), which is not present in mice, and 
LDLR90 have been identified as high-affinity 
receptors.109 In contrast, the specific receptor for 
CXCL4 has not yet been identified in mice. 
However, in some circumstances, CXCL4 can 
interact with other chemokines (e.g. CCL5) and 
thereby modulate their effects on target cells. A 
central role of platelet-derived CXCL4 was 
demonstrated in solid organs. In vivo, mice lacking 
CXCL4 are significantly protected from severe 
liver fibrosis, demonstrating the pro-fibrotic 
phenotype of this chemokine and that its effects in 
mice are indeed mediated by other receptors than 
CXCR3.110 In addition, it was shown that CXCL4 
is secreted not only by activated platelets, but also 
by plasmacytoid dendritic cells and fibroblasts in 
systemic sclerosis.111 Thus, these studies further 
involve Mks/platelets to pro- inflammatory and 
pro-fibrotic programmes in fibrosis. Interestingly, 
more than 30 years ago, Burstein et al. linked 
CXCL4 to myelofibrosis, by suggesting that 
abnormal Mks stimulate the proliferation of 
fibrosis-driving fibroblasts though the release of 
CXCL4.112 However, no correlation was seen 
between BM fibrosis and plasma levels or the 
platelet content of CXCL4 in the same study.112 
Recently, Schneider et al. using a mouse model 
with genetic fate tracing in vivo, provided 
evidence that Gli1+ cells are key players in the 
initiation and progression of BM fibrosis and that 
Mk-derived CXCL4 was necessary and sufficient 
to induce the migration of Gli1+ stromal cells and 
their myofibroblastic differentiation.113 In these 
experiments, CXCL4 was shown to induced 
myofibroblast differentiation of Gli1+ cells 
comparable to induction with TGF-β, a known 
stimulus for differentiation of MSCs into 
myofibroblasts.113 
 
Other cytokines. Oncostatin M (OSM), is a 
pleiotropic cytokine belonging to the interleukin-6 
(IL-6) family.114 Produced mainly by activated T 
cells and monocytes, OSM can elicit different 
biological effects, depending on the cell type. 
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OSM acts through two types of receptors. The 
type I OSM receptor is composed of gp130 and 
the leukemia inhibitory factor (LIF) receptor β-
subunit (LIFR), and the type II OSM receptor is 
composed of gp130 and the OSM-specific receptor 
β- subunit (OSMR).115 OSM has emerged as an 
important cytokine in the control of 
hematopoiesis. Transplantation experiments with 
OSM-deficient mice have shown that OSM 
stimulates stromal cells as well as hematopoietic 
progenitors and is required for the proper 
generation and maintenance of microenvironment 
in the BM.116,117 Noteworthy, BM Mks express 
substantial amounts of OSM,118 and OSM has 
been reported to behave as a megakaryocytic 
maturation factor in vitro and to augment platelet 
production in vivo.119 Within the context of 
myelofibrosis, JAK2 V617F mutation promotes 
expression of OSM in neoplastic myeloid cells 
and, consequently, OSM mRNA levels are 
increased in the BM of patients with MPNs 
compared to control patients.120 Mechanistically, 
OSM secreted by JAK2V617F+ cells stimulated 
growth of fibroblasts and endothelial cells by 
sustaining the production of angiogenic and pro-
fibrogenic cytokines.120 
Aberrant packaging of -granule-specific 
proteins is supposed to trigger myelofibrosis in 
patients with GPS. Using a Nbeal2-/- murine model 
of GPS, Guerrero et al. demonstrated that BM Mks 
from these mice were enriched in a restricted set 
of chemokines transcripts, namely CCL3 and 
CCL4, which encode macrophage inflammatory 
protein (MIP) 1 and 1, respectively, well-known 
pro- inflammatory chemokines increased in 
PMF.46 A peculiar role for MIP 1 in sustaining 
osteoblasts proliferation in MPN mice model has 
been also proposed.121 
Interleukin 8 (IL-8) is a member of the family 
of chemokines related by a CXC motif. It binds to 
CXC chemokine receptor 1 (CXCR1) and 2 
(CXCR2).122 It is produced by several cell types, 
including Mks123 and exhibits many biological 
functions in inflammation, HSC proliferation and 
mobilization and neo-angiogenesis. Increased 
levels of IL-8 were found in serum124 and plasma68 
of patients with PMF. Additionally, IL-8 and its 
receptors were reported to be involved in PMF-
altered Mk growth.124 Finally, rodents lack a direct 
homologue of IL-8, but the chemokines 
CXCL1/KC, CXCL2/MIP-2, and CXCL5-6/LIX 
are regarded as functional homologues of IL-8.125 
Finally,  Mks were repeatedly identified  as  the  
main cellular source of an increasing list of 
cytokines, which show higher plasma levels in 
PMF patients, and that are individually involved in 
the promotion of myelofibrosis. This list further 
includes bone morphogenic proteins (e.g. BMP- 
1126, BMP-2, -4, and -6127), Lipocalin-2 (LCN-
2),128 Fibroblasts Growth Factor (FGF),129 
Vascular Endothelial Growth Factor (VEGF),130 
Secreted Phospho Protein-1 (SPP1)131 and 
Thrombospondin- 1 (TSP-1).132,133 
 
Megakaryocyte expression of extracellular 
matrices and cross-linking enzymes in bone 
marrow fibrosis. Deregulated extracellular matrix 
(ECM) dynamics in terms of amount, composition 
and topography is a hallmark of BM fibrosis.1 This 
in turn potentiates the oncogenic effects of growth 
factor signaling pathways and alters cell behaviors 
during fibrosis progression. ECM components are 
not solely expressed by stromal cells, several 
evidences suggest that Mks may directly influence 
the biochemical properties and architecture of BM 
ECM both in physiological and pathological 
conditions.134 It is known that Mks can secrete 
various ECM components which are supposed to 
sustain Mk maturation and platelet release by 
creating a regulatory niche within the BM 
environment.135 Mks express different collagen 
types (e.g., III, IV), glycoproteins (e.g., 
Fibronectin and Thrombospondin) and 
proteoglycans. Interestingly, TPO has been 
recently recognized as a pivotal regulator of this 
new Mk function, by inducing TGF-β1 release and 
consequent activation of TGF- downstream 
signaling pathways, both in vitro and in vivo.136 
This activation led to a dose dependent increase of 
ECM component synthesis by Mks, which was 
reverted upon incubation with JAK and TGF-β1 
receptor specific inhibitors.136 
In parallel with ECM secretion, Mks express 
several modifiers of ECM structure. Factor XIII-A 
is synthesized by Mks and both protein and 
mRNA are packaged into the cytoplasm of 
forming platelets.137 Factor XIII-A belongs to 
transglutaminases, a class of calcium ion-
dependent enzymes that catalyze an acyl transfer 
reaction in which y-carboxamide groups of 
peptide-bound glutaminyl residues are acyl donors 
and primary amine including the -amino group of 
peptide-bound lysyl residues, are acyl acceptors. 
By this reaction, transglutaminases catalyze the 
formation of -(y- glutamy1) lysine linkages 
between proteins. Thus, based on these properties, 
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the potential role of FXIII-A in the BM 
environment may consist in the cross-link of 
extracellular fibrillar FN matrix with 
collagen.138,139 
LOX is a copper-dependent amine oxidase that 
catalyzes oxidative deamination of lysine and 
hydroxylysine residues on collagen and elastin, 
leading to cross-linking within these proteins and 
changes in ECM elasticity. Eliades et al., detected 
LOX expression in diploid-tetraploid Mks, but 
scarce traces in polyploid Mks and identified a 
peculiar role for this enzyme in BM fibrosis.84 
They found that in the GATA-1low mouse model, 
which is characterized by increased frequency of 
low ploidy Mks and extensive matrix of fibres, 
LOX was abundantly expressed by low ploidy 
Mks. More importantly, administration of β-
aminopropionitrile (a LOX inhibitor) to the 
GATA-1low mice inhibited the progression of 
myelofibrosis. Consistently, human platelets and 
Mks from patients with PMF overexpress LOX 
and show higher adhesion to collagen that is 
dependent on LOX activity.140 
In addition to cross-linking enzymes, also ECM 
degradation directly impacts cell behavior and 
migration. Metalloproteinases (MMPs) are a 
family of zinc-dependent endopeptidases and 
function in remodeling the ECM by its ability to 
degrade and cleave ECM components with wide 
substrate specificities.141 Once activated, the 
MMPs are subject to inhibition by the tissue 
inhibitors of metalloproteinases (TIMPs) that bind 
MMPs non-covalently and counteract their 
proteolytic activity. 
Mks synthetize several MMPs, particularly 
gelatinases MMP-2 and MMP-9.142 Moreover, 
transcripts for MMP-1, 11, 14, 15, 17, 19, 24 and 
25 have also been identified.26 Conversely, 
biosynthesis of TIMPs 1-4 in Mks/platelets 
intervenes in excessive tissue remodeling.143 It is 
suggested that BM fibrosis in PMF results from 
enhanced TIMP and decreased MMP activities. In 
particular, TIMP-1 (both the total, complex and 
the free form) is significantly increased in MPNs, 
while MMP-3 is significantly decreased, and 
levels of MMP-2 and MMP-9 are not different 
from control values.95,144 Further, membrane type 
1-MMP (MMP-14) was found overexpressed by 
up to 80-fold in advanced stages of fibrosis, and 
Mks and endothelial cells were unmasked as the 
major cellular source.145 By contrast, a 
significantly higher expression of neutrophil 
collagenase (MMP-8) was encountered in the pre-
fibrotic stages of PMF. Although the JAK-STAT 
signaling pathway is directly involved in the 
regulation of genes encoding MMPs, the altered 
expression of MMPs seem not influenced by the 
JAK2 mutation status but predominantly related to 
the stage of disease.145 
 
Direct Megakaryocyte-cell interactions in the 
context of bone marrow fibrosis. In addition to 
secretory events, one more pathophysiological 
mechanism operating in the development of 
myelofibrosis is the abnormal interaction of Mks 
with cell components of the BM (Figure 1). 
Selectins (CD62L, CD62P) and Mk glycoproteins 
(CD41a, CD42b) were demonstrated to mediate 
Mk-fibroblast interactions in human BM and to 
increase fibroblast growth.146 
Abnormalities in mesenchymal stem cells 
derived from PMF patients were reported to alter 
the ability of these cells to support Mk 
differentiation in vitro.147-149 Further, a 
pathological interaction, between 
polymorphonuclear (PMN) leukocytes and Mk, 
correlated with MF development, has been also 
proposed.17 Emperipolesis is the random passage 
of the different types of BM cells through Mk 
intracellular space. The phenomenon is strongly 
increased in BM of patients with MPN 
disorders.150 Schmitt et al., first showed both in the 
BM of patients with PMF, and in the TPOhigh 
murine model, abnormal subcellular P-selectin 
distribution, which appeared to correlate with 
excessive and pathological emperipolesis of PMN 
leukocytes within Mk.150 This abnormal 
interaction was considered the main cause of the 
destruction of Mk storage organelles and leakage 
of -granular contents into the BM 
microenvironment.151 As in patients, a similar 
pathologic neutrophil emperipolesis was detected 
in the GATA-1low mouse model of 
myelofibrosis.152 In BM Mk of these mice, P-
selectin, although normally expressed, was found 
frequently associated with the demarcation 
membrane system (DMS) instead of within 
granules. In addition, pathologic Mks were 
surrounded by myeloperoxidase-positive 
neutrophils, some of which appeared in the 
process to establish contact with Mks by fusing 
their membrane with those of the DMS. 
Quantification of this process revealed that 34% 
(in BM) of GATA-1(low) Mks contained 1 to 3 
neutrophils embedded in a vacuolated cytoplasm. 
The neutrophil-embedded GATA-1(low) Mks 
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displayed morphologic features compatible with 
those of cells dying from para-apoptosis, 
confirming the hypothesis that emperipolesis 
sustains myelofibrosis by driving the release of 
fibrogenic Mk cytokines and neutrophil proteases 
in the BM microenvironment.152 Moreover, 
abnormal localization of P-selectin in Mks and 
platelets, induced by the GATA-1(low) mutation, 
was further involved in the pathological 
interactions of circulating platelets with 
leucocytes, responsible for the increased presence 
of thrombosis seen in these mice,153 as well as, in 
the promotion of extramedullary hematopoiesis.154 
Consistently, high rate of emperipolesis is 
detectable in BM biopsies of patients with GPS, a 
rare inherited bleeding disorder characterized by 
deficiency of platelet α-granules, 
macrothrombocytopenia and marrow fibrosis.155 
 
Is the pro-fibrotic role of Megakaryocytes/ 
platelets restricted to the bone marrow? New 
discoveries in the field of thrombopoiesis and 
platelet roles have revealed unprecedented features 
of the Mk/Platelet lineage that open new avenues 
in the study of these cells, particularly in diseased 
conditions. Bioactive mediators, stored in 
platelets, have been implicated in fibrotic 
conditions that target solid organs, rather than BM 
(Table 2).  
A large amount of experimental evidence 
implies that platelets participate in the liver 
fibrotic process mainly by releasing pro- fibrotic 
mediators. Using mice carrying a Mk/platelet-
specific targeted conditional deletion of the TGF-
β1 gene (PF4CreTgf1f/f), Ghafoory et al. 
demonstrated that platelet TGF-β1 deficiency 
decreases liver fibrosis in a mouse model of 
carbon tetrachloride (CCl4)-induced liver injury.156 
However, there is also evidence that platelets 
under certain circumstances may have a protective 
role against liver fibrosis. To this regard, 
thrombocytopenic mice, with selective disruption 
of the anti-apoptotic gene Bcl-xL, were shown to 
be more prone to liver fibrosis by bile duct ligation 
compared to their wild type counterparts.157 The 
authors, suggested that the anti-fibrotic Hepatocyte 
Growth Factor (HGF) released from activated 
platelets in liver, attenuated the expression of 
collagen in hepatic stellate cells, the key cell type 
in liver fibrosis.157 Additionally, Mk-specific 
disruption of the TGF-1 gene resulted in mice 
protection from cardiac hypertrophy, fibrosis, and 
systolic dysfunction in response to transverse 
aortic constriction, suggesting that platelet 
profibrotic behavior is not solely restricted to the 
liver.158 Similarly, evidence has been accumulated 
implicating platelets in the pathogenesis of 
interstitial lung fibrosis in several animal models. 
Piguet et al. found that trapping of platelets in 
contact with the alveolar endothelium of the lungs 
after bleomycin injection was increased and 
correlated with the deposition of collagen.159 The 
authors suggested that this could represent not 
only a simple correlation but also a potential 
pathological mechanism that links platelets and 
pulmonary fibrosis. Interestingly, in a recent study 
platelets were shown to promote acute lung injury 
through the massive release of the Wnt/β-catenin 
inhibitor Dickkopf-1 (Dkk-1) from their α-
granules, leading to increased expression of 
vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1) on the 
surface of alveolar epithelial cells (AECs) and 
abnormal macrophage/neutrophils interaction with 
AECs.160 In addition to the direct involvement of 
platelets in fibrosis of solid organs, the potential 
contribution of Mks to organ fibrosis still needs to 
be uncovered. It is becoming increasingly clear 
that Mks transfer unique genetic codes to platelets, 
and that environmental changes can alter
 
Table 2. Megakaryocytes/Platelets contribution to organ fibrosis. 
Organ Role in fibrosis Mechanism Experimental model Ref. 
Liver 
 
Pro-fibrotic 
 
 
Release of TGF-1 
 
Platelet specific TGF-β1 deficiency in a mouse 
model of carbon tetrachloride (CCl4)-induced liver 
injury 
152 
Liver Anti-fibrotic Release of HGF 
Platelet specific Bcl-xl deficiency in a mouse 
model of bile duct ligation 
153 
Heart 
 
Pro-fibrotic 
 
Release of TGF-1 
Mk-specific TGF-1 deficiency in a mouse model 
of transverse aortic constriction 
154 
Lung Pro-fibrotic Trapping into alveolar endothelium  Bleomycin induced pulmonary fibrosis 155 
Lung Pro-fibrotic 
VCAM-1 and ICAM-1 upregulation 
in AECs due to Dkk-1 platelet 
release 
2-hit acute lung inflammation model with a 
moderate dose of lipopolysaccharide followed by a 
high tidal volume mechanical ventilation 
156 
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Figure 2. Schematic representation of potential novel mechanisms for MPN pathogenesis. 
transcriptional, translational, and post-translational 
processes in Mks, affecting the genetic code of 
platelets in circulation.161 Change in Mk-platelet 
transcriptional axis is a dynamic process, 
especially in disease situations, and can rapidly 
affect the platelet repertoire of messenger RNAs 
(mRNAs), microRNAs (miRNAs), and proteins 
that contribute to their primary and alternative 
functions. Freishtat et al., revealed for the first 
time, that a de novo transcriptome is imparted to 
platelets by BM residing Mks during sepsis.162 
Septic Mks produce platelets with acutely altered 
mRNA profiles, and these platelets mediate 
lymphotoxicity via the potent cytotoxic serine 
protease, granzyme B.162 Similarly, in the context 
of cancer, Mks of tumor-bearing mice endocytose 
circulating thrombospondin-1 (TSP-1) and 
increase its synthesis to produce platelets with 
elevated levels of TSP-1, one of the most potent 
angiogenesis inhibitors. These TSP-1-enriched 
platelets were shown to adhere to tumors and to 
act as potent inhibitors of angiogenesis and cancer 
growth.163 Thus, similar changes may occur in 
fibrotic conditions, but this has not been 
demonstrated yet. 
Conclusions. In this review, we summarized the 
involvement of the Mk lineage in the development 
of BM fibrosis. We now know that, in addition to 
genetic triggers, BM fibrosis is sustained by the 
intramedullary release of cytokines that are 
responsible for the abnormal activation of stromal 
cells, resulting in extensive deposits of reticulin 
and collagens. Mks are supposed to constitute the 
main source of these reactive cytokines. Abnormal 
Mk differentiation, apoptosis and emperipolesis 
were all proposed as major mechanisms for the 
enhanced release of cytokines with a fibrogenic 
potential. Unfortunately, mechanisms underlying 
Mk secretion, their relationships with other BM 
lineages and their functional activities in 
physiological conditions as well as during 
myelofibrosis progression, are not well understood 
to date. The first attempt to directly target the Mk 
lineage was shown, recently, to revert the disease 
in both Jak2V617F and MPLW515L mice models. 
Using a small molecule, the AURKA inhibitor 
MLN8237, that induce Mk polyploidization, 
differentiation, and subsequent apoptosis, the 
Crispino’s group demonstrated that the 
pharmacological induction of Mk maturation was 
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beneficial in terms of reduced burden of immature 
Mks and amelioration of PMF features, including 
BM fibrosis.164 Thus, developing drugs able to re-
establish Mk normal function may represent a new 
strategy to treat the disease and, at the same time, 
to understand its pathogenic mechanisms (Figure  
2). 
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